Trial Profile
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13 (TM) in Healthy Infants
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 16 May 2019 This trial has been completed in Spain as per European Clinical Trials Database record.
- 20 Sep 2018 Results published in the Vaccine
- 15 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.